HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ADMA Biologics, maintaining a price target of $18. Analyst Raghuram Selvaraju continues to support the stock, indicating confidence in its potential.
October 14, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ADMA Biologics, maintaining a price target of $18. Analyst Raghuram Selvaraju continues to support the stock, indicating confidence in its potential.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100